Medical - Care Facilities
Compare Stocks
4 / 10Stock Comparison
CCM vs USPH vs RDNT vs AFCG
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Medical - Diagnostics & Research
REIT - Specialty
CCM vs USPH vs RDNT vs AFCG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Care Facilities | Medical - Diagnostics & Research | REIT - Specialty |
| Market Cap | $748K | $897M | $4.45B | $73M |
| Revenue (TTM) | $366M | $695M | $2.04B | $6M |
| Net Income (TTM) | $-163M | $11M | $47M | $-20M |
| Gross Margin | -11.4% | 22.0% | 11.2% | -76.6% |
| Operating Margin | -131.0% | 12.2% | 3.0% | -124.7% |
| Forward P/E | 1.2x | 20.6x | 91.8x | — |
| Total Debt | $3.93B | $426M | $1.86B | $76M |
| Cash & Equiv. | $216M | $36M | $767M | $39M |
CCM vs USPH vs RDNT vs AFCG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Mar 21 | May 26 | Return |
|---|---|---|---|
| Concord Medical Ser… (CCM) | 100 | 13.4 | -86.6% |
| U.S. Physical Thera… (USPH) | 100 | 56.7 | -43.3% |
| RadNet, Inc. (RDNT) | 100 | 264.4 | +164.4% |
| Advanced Flower Cap… (AFCG) | 100 | 21.5 | -78.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CCM vs USPH vs RDNT vs AFCG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CCM is the #2 pick in this set and the best alternative if value and stability is your priority.
- Lower P/E (1.2x vs 91.8x)
- Beta 0.53 vs AFCG's 1.86
USPH is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 5 yrs, beta 0.93, yield 3.1%
- Rev growth 16.3%, EPS growth -22.8%, 3Y rev CAGR 12.2%
- Lower volatility, beta 0.93, Low D/E 55.3%, current ratio 1.01x
- Beta 0.93, yield 3.1%, current ratio 1.01x
RDNT carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 9.5% 10Y total return vs USPH's 22.6%
- 2.3% margin vs AFCG's -333.9%
- +4.6% vs AFCG's -35.5%
- 1.3% ROA vs AFCG's -6.4%, ROIC 2.0% vs -4.1%
AFCG lags the leaders in this set but could rank higher in a more targeted comparison.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.3% revenue growth vs AFCG's -39.6% | |
| Value | Lower P/E (1.2x vs 91.8x) | |
| Quality / Margins | 2.3% margin vs AFCG's -333.9% | |
| Stability / Safety | Beta 0.53 vs AFCG's 1.86 | |
| Dividends | 3.1% yield, 5-year raise streak, vs AFCG's 28.1%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +4.6% vs AFCG's -35.5% | |
| Efficiency (ROA) | 1.3% ROA vs AFCG's -6.4%, ROIC 2.0% vs -4.1% |
CCM vs USPH vs RDNT vs AFCG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
CCM vs USPH vs RDNT vs AFCG — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
USPH leads in 2 of 6 categories
CCM leads 1 • RDNT leads 1 • AFCG leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
USPH leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
RDNT is the larger business by revenue, generating $2.0B annually — 342.1x AFCG's $6M. RDNT is the more profitable business, keeping 2.3% of every revenue dollar as net income compared to AFCG's -3.3%. On growth, AFCG holds the edge at +64.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $366M | $695M | $2.0B | $6M |
| EBITDAEarnings before interest/tax | -$359M | $107M | $214M | -$16M |
| Net IncomeAfter-tax profit | -$163M | $11M | $47M | -$20M |
| Free Cash FlowCash after capex | $0 | $67M | -$178M | -$24M |
| Gross MarginGross profit ÷ Revenue | -11.4% | +22.0% | +11.2% | -76.6% |
| Operating MarginEBIT ÷ Revenue | -131.0% | +12.2% | +3.0% | -124.7% |
| Net MarginNet income ÷ Revenue | -44.6% | +1.5% | +2.3% | -3.3% |
| FCF MarginFCF ÷ Revenue | -2.1% | +9.6% | -8.7% | -3.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -8.3% | +7.7% | +14.8% | +64.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +84.0% | -115.0% | -114.1% | +16.7% |
Valuation Metrics
CCM leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, USPH's 12.5x EV/EBITDA is more attractive than RDNT's 25.9x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $748,461 | $897M | $4.5B | $73M |
| Enterprise ValueMkt cap + debt − cash | $547M | $1.3B | $5.5B | $110M |
| Trailing P/EPrice ÷ TTM EPS | -0.02x | 41.55x | -230.00x | -3.25x |
| Forward P/EPrice ÷ next-FY EPS est. | 1.23x | 20.63x | 91.75x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 12.52x | 25.88x | — |
| Price / SalesMarket cap ÷ Revenue | 0.01x | 1.15x | 2.18x | 2.32x |
| Price / BookPrice ÷ Book value/share | 0.00x | 1.16x | 3.19x | 0.39x |
| Price / FCFMarket cap ÷ FCF | — | 14.71x | 52.01x | 6.47x |
Profitability & Efficiency
USPH leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
RDNT delivers a 3.8% return on equity — every $100 of shareholder capital generates $4 in annual profit, vs $-11 for AFCG. AFCG carries lower financial leverage with a 0.43x debt-to-equity ratio, signaling a more conservative balance sheet compared to CCM's 2.43x. On the Piotroski fundamental quality scale (0–9), USPH scores 5/9 vs CCM's 3/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -9.8% | +1.4% | +3.8% | -11.1% |
| ROA (TTM)Return on assets | -2.4% | +0.9% | +1.3% | -6.4% |
| ROICReturn on invested capital | -7.7% | +5.6% | +2.0% | -4.1% |
| ROCEReturn on capital employed | -12.2% | +7.6% | +2.1% | -5.6% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 | 5 | 4 |
| Debt / EquityFinancial leverage | 2.43x | 0.55x | 1.37x | 0.43x |
| Net DebtTotal debt minus cash | $3.7B | $390M | $1.1B | $38M |
| Cash & Equiv.Liquid assets | $216M | $36M | $767M | $39M |
| Total DebtShort + long-term debt | $3.9B | $426M | $1.9B | $76M |
| Interest CoverageEBIT ÷ Interest expense | -2.40x | 15.42x | 1.46x | -2.15x |
Total Returns (Dividends Reinvested)
RDNT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RDNT five years ago would be worth $24,710 today (with dividends reinvested), compared to $1,512 for CCM. Over the past 12 months, RDNT leads with a +4.6% total return vs AFCG's -35.5%. The 3-year compound annual growth rate (CAGR) favors RDNT at 26.0% vs CCM's -27.2% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +20.4% | -24.6% | -19.0% | +10.2% |
| 1-Year ReturnPast 12 months | -28.4% | -14.3% | +4.6% | -35.5% |
| 3-Year ReturnCumulative with dividends | -61.4% | -43.7% | +100.0% | -20.1% |
| 5-Year ReturnCumulative with dividends | -84.9% | -43.4% | +147.1% | -44.6% |
| 10-Year ReturnCumulative with dividends | -88.8% | +22.6% | +947.4% | -42.4% |
| CAGR (3Y)Annualised 3-year return | -27.2% | -17.4% | +26.0% | -7.2% |
Risk & Volatility
Evenly matched — CCM and RDNT each lead in 1 of 2 comparable metrics.
Risk & Volatility
CCM is the less volatile stock with a 0.53 beta — it tends to amplify market swings less than AFCG's 1.86 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RDNT currently trades 67.0% from its 52-week high vs CCM's 47.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.53x | 0.93x | 1.43x | 1.86x |
| 52-Week HighHighest price in past year | $10.77 | $93.50 | $85.84 | $5.87 |
| 52-Week LowLowest price in past year | $3.18 | $58.55 | $50.76 | $2.06 |
| % of 52W HighCurrent price vs 52-week peak | +47.7% | +63.1% | +67.0% | +52.6% |
| RSI (14)Momentum oscillator 0–100 | 67.5 | 46.1 | 51.3 | 48.2 |
| Avg Volume (50D)Average daily shares traded | 11K | 171K | 822K | 235K |
Analyst Outlook
Evenly matched — USPH and AFCG each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: CCM as "Buy", USPH as "Buy", RDNT as "Buy". Consensus price targets imply 72.9% upside for USPH (target: $102) vs 60.0% for RDNT (target: $92). For income investors, AFCG offers the higher dividend yield at 28.10% vs USPH's 3.06%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | — |
| Price TargetConsensus 12-month target | — | $102.00 | $92.00 | — |
| # AnalystsCovering analysts | 2 | 12 | 11 | — |
| Dividend YieldAnnual dividend ÷ price | — | +3.1% | — | +28.1% |
| Dividend StreakConsecutive years of raises | 0 | 5 | 0 | 0 |
| Dividend / ShareAnnual DPS | — | $1.80 | — | $0.87 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.6% | 0.0% | 0.0% |
USPH leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CCM leads in 1 (Valuation Metrics). 2 tied.
CCM vs USPH vs RDNT vs AFCG: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is CCM or USPH or RDNT or AFCG a better buy right now?
For growth investors, U.
S. Physical Therapy, Inc. (USPH) is the stronger pick with 16. 3% revenue growth year-over-year, versus -39. 6% for Advanced Flower Capital Inc. (AFCG). U. S. Physical Therapy, Inc. (USPH) offers the better valuation at 41. 5x trailing P/E (20. 6x forward), making it the more compelling value choice. Analysts rate Concord Medical Services Holdings Limited (CCM) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CCM or USPH or RDNT or AFCG?
On forward P/E, Concord Medical Services Holdings Limited is actually cheaper at 1.
2x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — CCM or USPH or RDNT or AFCG?
Over the past 5 years, RadNet, Inc.
(RDNT) delivered a total return of +147. 1%, compared to -84. 9% for Concord Medical Services Holdings Limited (CCM). Over 10 years, the gap is even starker: RDNT returned +947. 4% versus CCM's -88. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CCM or USPH or RDNT or AFCG?
By beta (market sensitivity over 5 years), Concord Medical Services Holdings Limited (CCM) is the lower-risk stock at 0.
53β versus Advanced Flower Capital Inc. 's 1. 86β — meaning AFCG is approximately 250% more volatile than CCM relative to the S&P 500. On balance sheet safety, Advanced Flower Capital Inc. (AFCG) carries a lower debt/equity ratio of 43% versus 2% for Concord Medical Services Holdings Limited — giving it more financial flexibility in a downturn.
05Which is growing faster — CCM or USPH or RDNT or AFCG?
By revenue growth (latest reported year), U.
S. Physical Therapy, Inc. (USPH) is pulling ahead at 16. 3% versus -39. 6% for Advanced Flower Capital Inc. (AFCG). On earnings-per-share growth, the picture is similar: Concord Medical Services Holdings Limited grew EPS -3. 6% year-over-year, compared to -768. 4% for RadNet, Inc.. Over a 3-year CAGR, RDNT leads at 12. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CCM or USPH or RDNT or AFCG?
RadNet, Inc.
(RDNT) is the more profitable company, earning 2. 3% net margin versus -80. 3% for Concord Medical Services Holdings Limited — meaning it keeps 2. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: USPH leads at 10. 3% versus -138. 6% for CCM. At the gross margin level — before operating expenses — AFCG leads at 90. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CCM or USPH or RDNT or AFCG more undervalued right now?
On forward earnings alone, Concord Medical Services Holdings Limited (CCM) trades at 1.
2x forward P/E versus 91. 8x for RadNet, Inc. — 90. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for USPH: 72. 9% to $102. 00.
08Which pays a better dividend — CCM or USPH or RDNT or AFCG?
In this comparison, AFCG (28.
1% yield), USPH (3. 1% yield) pay a dividend. CCM, RDNT do not pay a meaningful dividend and should not be held primarily for income.
09Is CCM or USPH or RDNT or AFCG better for a retirement portfolio?
For long-horizon retirement investors, U.
S. Physical Therapy, Inc. (USPH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 93), 3. 1% yield). Advanced Flower Capital Inc. (AFCG) carries a higher beta of 1. 86 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (USPH: +22. 6%, AFCG: -42. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CCM and USPH and RDNT and AFCG?
These companies operate in different sectors (CCM (Healthcare) and USPH (Healthcare) and RDNT (Healthcare) and AFCG (Real Estate)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: CCM is a small-cap quality compounder stock; USPH is a small-cap high-growth stock; RDNT is a small-cap quality compounder stock; AFCG is a small-cap income-oriented stock. USPH, AFCG pay a dividend while CCM, RDNT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.